PTC Therapeutics Inc. (NASDAQ:PTCT) shares fell 7.9% during trading on Monday . The company traded as low as $6.27 and last traded at $6.61, with a volume of 1,600,123 shares trading hands. The stock had previously closed at $7.18.

A number of research firms recently commented on PTCT. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $39.00 price target on shares of PTC Therapeutics in a research note on Sunday, April 17th. Credit Suisse Group AG downgraded PTC Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Tuesday. Zacks Investment Research raised PTC Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Wedbush lowered their target price on PTC Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Jefferies Group reissued a “hold” rating and set a $8.00 target price on shares of PTC Therapeutics in a research note on Friday, May 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $35.97.

The company’s 50 day moving average is $7.07 and its 200 day moving average is $10.99. The company’s market cap is $196.05 million.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($1.22) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.04. During the same quarter in the prior year, the business earned ($1.15) EPS. The company earned $18.90 million during the quarter, compared to the consensus estimate of $13.74 million. The firm’s revenue for the quarter was up 152.0% compared to the same quarter last year. On average, equities analysts predict that PTC Therapeutics Inc. will post ($4.93) EPS for the current fiscal year.

A number of hedge funds and institutional investors recently modified their holdings of the company. ProShare Advisors LLC increased its position in shares of PTC Therapeutics by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 3,122 shares in the last quarter. Rhumbline Advisers boosted its stake in PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 2,485 shares during the last quarter. Marshall Wace LLP boosted its stake in PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock valued at $1,439,000 after buying an additional 14,926 shares during the last quarter. Turner Investments L.P. acquired a new stake in PTC Therapeutics during the fourth quarter valued at $1,532,000. Finally, California State Teachers Retirement System boosted its stake in PTC Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 62,719 shares of the biopharmaceutical company’s stock valued at $2,032,000 after buying an additional 1,100 shares during the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.